Login to Your Account

Another Obesity Drug Down

Amylin and Takeda Discontinue Pramlintide/Metreleptin Program

By Tom Wall

Monday, August 8, 2011
Amylin Pharmaceuticals Inc. and partner Takeda Pharmaceutical Co. Ltd. have discontinued development of combination obesity candidate pramlintide/metreleptin after what they described as a "commercial reassessment" of a revised development plan and the "evolving dynamics" of obesity therapeutics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription